Genfit S.A. Files 6-K, Announces Press Release
| Field | Detail |
|---|---|
| Company | Genfit S.A. |
| Form Type | 6-K |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
Genfit dropped a 6-K with a press release today - check it for news.
AI Summary
Genfit S.A. filed a Form 6-K on April 29, 2025, reporting a press release dated the same day. The company, a biopharmaceutical firm focused on metabolic, inflammatory, and autoimmune diseases, is based in Loos, France. This filing does not contain specific financial figures or operational updates beyond the announcement of the press release.
Why It Matters
This filing indicates Genfit S.A. is making a public announcement, which could contain significant updates relevant to investors and the company's strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine report of a press release and does not contain new financial data or significant operational changes that would immediately impact risk.
Key Players & Entities
- Genfit S.A. (company) — Registrant
- Pascal Prigent (person) — Chief Executive Officer
- April 29, 2025 (date) — Date of report
FAQ
What is the primary business of Genfit S.A.?
Genfit S.A. is a biopharmaceutical company focused on metabolic, inflammatory, and autoimmune diseases.
What is the filing date of this Form 6-K?
The Form 6-K was filed on April 29, 2025.
What exhibit is included with this Form 6-K?
Exhibit 99.1, a Press Release dated April 29, 2025, is included with this Form 6-K.
Where is Genfit S.A. headquartered?
Genfit S.A. is headquartered in Loos, France, at Parc Eurasanté, 885, avenue Eugéne Avinèe.
Does Genfit S.A. file annual reports under Form 20-F or 40-F?
Genfit S.A. files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 29, 2025 by Pascal Prigent regarding Genfit S.A..